Direct-to-Patient Pharma Programs and What They Change for Media
How direct-to-patient pharma programs change DTC media, measurement, and compliance, plus evaluation factors for DTP healthcare and pharmacy platforms.
The short answer
Direct-to-patient (DTP) pharma programs, such as LillyDirect and PfizerForAll (both launched in 2024), connect patients to independent telehealth, pharmacy delivery, and sometimes cash pricing. For media, they give DTC ads a branded destination that can end in a fill, which shortens the funnel and makes measurement more direct. They also bring new compliance and privacy questions, so evaluate DTP platforms on prescriber independence, fulfillment, pricing, data terms, and measurement access.
For most of DTC history, the ad's job ended at "ask your doctor." What happened next (an appointment, a prescription, a pharmacy, a payer decision) was outside the brand's view. Manufacturer DTP programs change that by building a path from the brand to the fill. For media teams, this is the biggest structural change in DTC in years. This article is part of the series that starts with the DTC pharma marketing guide.
What direct-to-patient pharma programs are
A DTP program is a manufacturer platform that helps a patient move from interest to treatment. The common components:
- Telehealth connection. Links to independent telehealth providers who evaluate the patient and decide whether to prescribe.
- Pharmacy fulfillment. Partnerships with mail or digital pharmacies that deliver the medication.
- Pricing options. Savings programs for commercially insured patients and, for some products, a cash price for patients paying out of pocket.
- Support. Educational content, refill reminders, and links to patient services.
Eli Lilly's LillyDirect launched in early 2024 and Pfizer's PfizerForAll in 2024. Other manufacturers have followed, and federal attention to direct purchasing and drug pricing in 2025 added momentum. Program features change often, so check each platform directly rather than relying on any summary, including this one. For how DTP relates to other forms of DTC, see what DTC means in healthcare.
What DTP changes for media
The call to action gets specific
Instead of "ask your doctor," the ad can say "see if it's right for you" and link to a path that includes a telehealth visit. The click has a clear next step. That tends to make digital channels, especially search and social, more measurable on actions.
The funnel gets shorter, and attribution gets tempting
When a patient can go from ad to telehealth to fill in days, last-click attribution looks persuasive. Be careful. Many DTP users would have found the platform anyway through search or news coverage. Incremental measurement still requires a comparison group.
Cash pay changes the measurement picture
Prescriptions filled at a cash price through a DTP pharmacy may not show up in the claims data your outcome vendor uses. If a growing share of your starts goes through DTP, your Rx measurement can understate media impact unless the vendor has coverage of that channel. Ask; see how to choose a DTC measurement platform.
Audience and creative shift
DTP works best for conditions where patients are motivated, the diagnosis is relatively straightforward, and telehealth evaluation is clinically reasonable. Obesity, migraine, and some chronic conditions fit. The GLP-1 category shows how fast this can move; see GLP-1 DTC advertising strategy.
Compliance questions DTP raises
None of this is legal advice, but these come up in every review:
- Prescriber independence. The telehealth provider must make an independent clinical decision. Ads and platform design should not imply a prescription is guaranteed.
- Fair balance on the platform. The DTP site is promotional labeling in the eyes of most reviewers, so it needs full risk information and balance.
- Remuneration and fraud and abuse. Arrangements between manufacturers, telehealth providers, and pharmacies draw scrutiny under federal fraud and abuse laws, especially where federal health care program patients are involved. HHS OIG publishes compliance resources.
- Privacy on intake. Telehealth intake collects health information. Pixels and tags on those pages need strict governance, as covered in tracking pixel governance on pharma websites.
DTP healthcare and pharmacy platform evaluation factors
| Factor | What to ask | Why it matters for media |
|---|---|---|
| Telehealth independence | How are prescribers selected, paid, and kept independent? | Shapes what the ad can promise |
| Pharmacy network | Which pharmacies fulfill, in which states, how fast? | Geographic targeting and fulfillment gaps |
| Pricing and coverage | Cash price, savings programs, payer handling | Messaging and audience fit |
| Data sharing terms | What data flows back to the brand, in what form? | Decides what you can measure |
| Privacy and tag governance | Which tags fire on intake and checkout pages? | Legal exposure under HHS, FTC, and state rules |
| Measurement access | Can conversions be reported in aggregate to media partners or a measurement vendor? | Optimization and incrementality |
| Patient experience | Steps, wait times, drop-off points | Paid traffic wasted on a poor flow |
| Safety reporting | How are adverse events and complaints captured and routed? | Required pharmacovigilance |
Measurement design for DTP traffic
- Define the conversion events you can legally and contractually receive (for example, aggregate counts of completed visits, not individual records).
- Keep a geographic or audience holdout so DTP conversions can be compared with a baseline.
- Reconcile DTP fills with your Rx vendor's coverage so starts are not double counted or missed.
- Track drop-off between landing, intake, visit, and fill. Media often gets blamed for problems in the flow.
Practical takeaway
If your brand has or is building a DTP path, map every page from ad click to fill and list which tags fire on each one and what data each partner receives. Review that map with privacy and legal before increasing paid traffic, and use it to agree on the one aggregate conversion signal your media partners will optimize to.
Frequently asked questions
What is a direct-to-patient pharma program?
It is a manufacturer-run platform that connects patients to care and medication, typically by linking to independent telehealth providers, pharmacy fulfillment, and savings or cash price options. Examples launched in 2024 include LillyDirect and PfizerForAll. Program details change, so check each one directly.
How does DTP change DTC media?
The ad can now point to a branded path that may end in a prescription and delivery, which shortens the funnel and makes conversion measurement more direct. It also raises compliance questions about the independence of prescribers and privacy questions about tracking on intake flows.
What factors should be used to evaluate DTP healthcare and pharmacy platforms?
Key factors include telehealth prescriber independence, pharmacy network and fulfillment, pricing and payer coverage options, data sharing terms, privacy and pixel governance, measurement access, patient experience, and how the platform handles adverse events and complaints.
Sources
- FDA, Basics of Drug Ads
- HHS, Use of Online Tracking Technologies by HIPAA Covered Entities and Business Associates
- FTC, Health Breach Notification Rule: The Basics for Business
- OIG, HHS Office of Inspector General Compliance Resources
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.